Publications
Publications
Show Results For
- All HBS Web
(939)
- Faculty Publications (488)
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
- January 2011 (Revised January 2012)
- Supplement
The Case of the Unidentified Healthcare Companies2010 (CW)
By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- January 2011 (Revised January 2012)
- Case
The Case of the Unidentified Healthcare Companies2010
By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- November 2010
- Supplement
Hikma Pharmaceuticals (B)
By: John A. Quelch
By 2009, Hikma Pharmaceuticals operated 13 manufacturing plants in 8 countries of which 5 were approved by the U.S. Food and Drug Administration. Hikma tracked its sales revenues over the period to show where the largest contributors were from. View Details
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details
- October 2010 (Revised August 2016)
- Case
On Weldon's Watch: Recalls at Johnson & Johnson from 2009 to 2010
By: Clayton S. Rose, Sandra J. Sucher, Rachel Gordon and Matthew Preble
In October of 2010, Johnson & Johnson (J&J) was unable to extricate itself from a year long recall crisis that had subjected the firm to criticism from Congress and regulators, resulted in the resignation of one of the firm's most senior officers, and cost hundreds of... View Details
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
- September 2010
- Teaching Note
Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)
By: Willy C. Shih
Teaching Note for 611009. View Details
- July 2010
- Case
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details
- June 2010 (Revised April 2017)
- Teaching Note
Pfizer: Letter from the Chairman (A) and (B)
By: Robert Simons and Kathryn Rosenberg
Teaching Note for 110003 and 110004. View Details
- June 2010 (Revised February 2013)
- Background Note
The Precautionary Principle
By: Michael W. Toffel and Nazli Z. Uludere Aragon
This note describes the precautionary principle and its key tenets, highlights challenges associated with its use, and includes many examples of its application, primarily within the realm of regulating activities based on the risk of harm to human health and the... View Details
- May 2010 (Revised June 2010)
- Supplement
Pfizer: Letter from the Chairman (B)
By: Robert L. Simons and Kathryn Rosenberg
This case continues the story begun in "Pfizer: A Letter from the Chairman" (HBS No. 110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report. View Details
- April 2010
- Case
Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Metabical is a new weight loss drug from Cambridge Sciences Pharmaceuticals intended for moderately overweight individuals. In anticipation of final FDA approval, the senior director of marketing, Barbara Printup, prepares for the product launch and must make several... View Details
- April 2010
- Teaching Note
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
Teaching Note for [607008]. View Details
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
- 2010
- Working Paper
Accelerating Energy Innovation: Insights from Multiple Sectors
By: Rebecca Henderson and Richard G. Newell
A combination of concerns about climate change and energy security has recently led to significant increases in public funding for energy R&D. Some commentators are suggesting that these increases need to be sustained, and are advocating for increases of as much as... View Details
- December 2009 (Revised April 2010)
- Teaching Note
GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)
Teaching Note for [605074] and [605075]. View Details
- November 2009 (Revised December 2009)
- Case
GTC Biotherapeutics: Developing Medicines in the Milk of Goats
By: Ray A. Goldberg and Sarah Morton
GTC is the first company in the animal world to receive FDA approval of a transgenic pharmaceutical. What are the implications for other firms in plants and animals and their opportunities to produce new medicines in an economical and safe fashion? View Details